Faculty of Pharmacy, Middle East University, Amman, Jordan.
Faculty of Pharmacy, Middle East University, Amman, Jordan.
Microb Pathog. 2022 Oct;171:105729. doi: 10.1016/j.micpath.2022.105729. Epub 2022 Sep 2.
As of 2022, the global population has access to several mRNA and traditional inactivated vaccines. However, their effectiveness in preventing infection, hospitalization, and COVID-associated mortality in Jordan has yet to be evaluated. The purpose of this observational study was to evaluate the relative effectiveness of three approved vaccines against COVID-19 in a sample of the Jordanian population. The study was conducted between July 2021 and 2022 in a sample of adult patients presenting to hospitals across Jordan and receiving one of the three vaccines - Pfizer (BNT162b2), Astra Zeneca (ChAdOx1-S), or Sinopharm (BBIBP-CorV). Data were collected to measure the rates of infection without hospitalization, infection with hospitalization, and death. The sample included patients with one of the following chronic conditions: cardiovascular disease, respiratory disease, or diabetes. Primary data were obtained from patients' health records. The sample included 6132 adults from Jordan, with a mean age 52 ± 17 years. The rates of death in patients receiving two doses of any vaccine ranged between 0.175 and 2.77%, compared with 0.69-13.53% in patients receiving only one dose. The rates of hospitalization were 6-7.97% with two doses, compared to 7.98-25.13% with one dose. The rates of infection without hospitalization were significantly higher in the two-dose group (6-25.1%) compared with those who had received only one dose of any COVID-19 vaccine (0.69-10.61%). In conclusion, receiving two doses of a COVID-19 vaccine was associated with lower odds of mortality and hospitalization and higher odds of infection. More research is needed to evaluate the safety and efficacy of vaccines against SARS-CoV-2.
截至 2022 年，全球已有多种 mRNA 和传统灭活疫苗可供使用。然而，它们在约旦预防感染、住院和与 COVID 相关的死亡率方面的效果尚未得到评估。本观察性研究的目的是评估在约旦人群样本中，三种已批准的 COVID-19 疫苗的相对有效性。该研究于 2021 年 7 月至 2022 年在约旦各地医院就诊的成年患者样本中进行，这些患者接受了三种疫苗中的一种，即辉瑞（BNT162b2）、阿斯利康（ChAdOx1-S）或国药控股（BBIBP-CorV）。收集数据以衡量无住院感染、住院感染和死亡的发生率。样本包括患有以下慢性疾病之一的患者：心血管疾病、呼吸道疾病或糖尿病。主要数据来自患者的健康记录。该样本包括来自约旦的 6132 名成年人，平均年龄为 52 ± 17 岁。接受任何两剂疫苗的患者的死亡率在 0.175%至 2.77%之间，而接受一剂疫苗的患者的死亡率在 0.69%至 13.53%之间。接受两剂疫苗的患者住院率为 6-7.97%，而接受一剂疫苗的患者住院率为 7.98-25.13%。未住院感染的发生率在两剂组中明显更高（6-25.1%），而接受任何一种 COVID-19 疫苗一剂的患者的发生率（0.69-10.61%）。总之，接种两剂 COVID-19 疫苗与死亡率和住院率降低以及感染率升高相关。需要更多研究来评估针对 SARS-CoV-2 的疫苗的安全性和有效性。
